{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:30:20Z","timestamp":1777509020200,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,5,28]],"date-time":"2015-05-28T00:00:00Z","timestamp":1432771200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin J Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s40880-015-0015-9","type":"journal-article","created":{"date-parts":[[2015,5,27]],"date-time":"2015-05-27T10:54:42Z","timestamp":1432724082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival"],"prefix":"10.1186","volume":"34","author":[{"given":"Kai-Lin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Lan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Qiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Yong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De-Hui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Lucas","family":"Wirian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Qing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,28]]},"reference":[{"key":"15_CR1","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","volume":"337","author":"WM Lee","year":"1997","unstructured":"Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733\u201345.","journal-title":"N Engl J Med"},{"key":"15_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"15_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379\u201391.","journal-title":"Lancet Oncol"},{"key":"15_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","volume":"27","author":"W Yeo","year":"2009","unstructured":"Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605\u201311.","journal-title":"J Clin Oncol"},{"key":"15_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/jmv.1890320412","volume":"32","author":"LN Shih","year":"1990","unstructured":"Shih LN, Sheu JC, Wang JT, Huang GT, Yang PM, Lee HS, et al. Serum hepatitis B virus DNA in healthy HBsAg-negative Chinese adults evaluated by polymerase chain reaction. J Med Virol. 1990;32:257\u201360.","journal-title":"J Med Virol"},{"key":"15_CR6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","volume":"22","author":"AM Evens","year":"2011","unstructured":"Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170\u201380.","journal-title":"Ann Oncol"},{"key":"15_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","volume":"89","author":"SN Pei","year":"2010","unstructured":"Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89:255\u201362.","journal-title":"Ann Hematol"},{"key":"15_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association For The Study Of The Liver","year":"2012","unstructured":"European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u201385.","journal-title":"J Hepatol"},{"key":"15_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","volume":"131","author":"CK Hui","year":"2006","unstructured":"Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59\u201368.","journal-title":"Gastroenterology"},{"key":"15_CR10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00277-011-1241-0","volume":"90","author":"YX Koo","year":"2011","unstructured":"Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative\/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90:1219\u201323.","journal-title":"Ann Hematol"},{"key":"15_CR11","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1093\/annonc\/mdp230","volume":"20","author":"N Fukushima","year":"2009","unstructured":"Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009;20:2013\u20137.","journal-title":"Ann Oncol"},{"key":"15_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1600-0609.2010.01474.x","volume":"85","author":"D Ji","year":"2010","unstructured":"Ji D, Cao J, Hong X, Li J, Wang J, Chen F, et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative\/HBcAb-positive: a multicenter retrospective study. Eur J Haematol. 2010;85:243\u201350.","journal-title":"Eur J Haematol"},{"key":"15_CR13","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1002\/cncr.25253","volume":"116","author":"K Matsue","year":"2010","unstructured":"Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. 2010;116:4769\u201376.","journal-title":"Cancer"},{"key":"15_CR14","volume-title":"World health organization classification of tumours of the haematopoietic and lymphoid tissues","author":"SHCE Swerdlow","year":"2008","unstructured":"Swerdlow SHCE, Harris NL, Jaffe ES, Stein H, Thiele J, et al. World health organization classification of tumours of the haematopoietic and lymphoid tissues. Pileri SA: IARC Press; 2008."},{"key":"15_CR15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2004.05.161","volume":"22","author":"W Yeo","year":"2004","unstructured":"Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22:927\u201334.","journal-title":"J Clin Oncol"},{"key":"15_CR16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","volume":"100","author":"AS Lok","year":"1991","unstructured":"Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182\u20138.","journal-title":"Gastroenterology"},{"key":"15_CR17","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373\u201380.","journal-title":"J Clin Oncol"},{"key":"15_CR18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187\u2013220.","journal-title":"J R Stat Soc B"},{"key":"15_CR19","first-page":"554","volume":"91","author":"F Marcucci","year":"2006","unstructured":"Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin\u2019s lymphoma. Haematologica. 2006;91:554\u20137.","journal-title":"Haematologica"},{"key":"15_CR20","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/cncr.22549","volume":"109","author":"F Wang","year":"2007","unstructured":"Wang F, Xu RH, Han B, Shi YX, Luo HY, Jiang WQ, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer. 2007;109:1360\u20134.","journal-title":"Cancer"},{"key":"15_CR21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1349-7006.2002.tb01280.x","volume":"93","author":"JH Kim","year":"2002","unstructured":"Kim JH, Bang YJ, Park BJ, Yoo T, Kim CW, Kim TY, et al. Hepatitis B virus infection and B-cell non-Hodgkin\u2019s lymphoma in a hepatitis B endemic area: a case\u2013control study. Jpn J Cancer Res. 2002;93:471\u20137.","journal-title":"Jpn J Cancer Res"},{"key":"15_CR22","first-page":"294","volume":"26","author":"XT Qin","year":"2007","unstructured":"Qin XT, Lu Y, Chen XQ, Xu HP, Fan HJ. Correlation of hepatitis B virus infection to non-Hodgkin\u2019s lymphoma. Chin J Cancer. 2007;26:294\u20137.","journal-title":"Chin J Cancer"},{"key":"15_CR23","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(10)70167-4","volume":"11","author":"EA Engels","year":"2010","unstructured":"Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11:827\u201334.","journal-title":"Lancet Oncol"},{"key":"15_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/CEJ.0b013e3283498e87","volume":"21","author":"F Wang","year":"2012","unstructured":"Wang F, Yuan S, Teng KY, Garcia-Prieto C, Luo HY, Zeng MS, et al. High hepatitis B virus infection in B-cell lymphoma tissue and its potential clinical relevance. Eur J Cancer Prev. 2012;21:261\u20137.","journal-title":"Eur J Cancer Prev"},{"key":"15_CR25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.dld.2006.12.017","volume":"39","author":"A Marzano","year":"2007","unstructured":"Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397\u2013408.","journal-title":"Dig Liver Dis"},{"key":"15_CR26","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1002\/hep.22945","volume":"49","author":"JH Hoofnagle","year":"2009","unstructured":"Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156\u201365.","journal-title":"Hepatology"},{"key":"15_CR27","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1365-2893.2010.01386.x","volume":"18","author":"HR Li","year":"2011","unstructured":"Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011;18:877\u201383.","journal-title":"J Viral Hepat"},{"key":"15_CR28","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1002\/hep.26718","volume":"59","author":"C Hsu","year":"2014","unstructured":"Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59:2092\u2013100.","journal-title":"Hepatology"},{"key":"15_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0166-3542(01)00176-0","volume":"52","author":"I Chemin","year":"2001","unstructured":"Chemin I, Jeantet D, Kay A, Trepo C. Role of silent hepatitis B virus in chronic hepatitis B surface antigen(\u2212) liver disease. Antiviral Res. 2001;52:117\u201323.","journal-title":"Antiviral Res"},{"key":"15_CR30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.tox.2007.11.021","volume":"245","author":"J Ozer","year":"2008","unstructured":"Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008;245:194\u2013205.","journal-title":"Toxicology"},{"key":"15_CR31","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/j.1572-0241.2003.07486.x","volume":"98","author":"JM Clark","year":"2003","unstructured":"Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960\u20137.","journal-title":"Am J Gastroenterol"},{"key":"15_CR32","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","volume":"110","author":"R Stasi","year":"2007","unstructured":"Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110:2924\u201330.","journal-title":"Blood"},{"key":"15_CR33","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00277-004-0899-y","volume":"83","author":"MS Dai","year":"2004","unstructured":"Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol. 2004;83:769\u201374.","journal-title":"Ann Hematol"},{"key":"15_CR34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1517\/14740338.4.3.599","volume":"4","author":"Y Tsutsumi","year":"2005","unstructured":"Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf. 2005;4:599\u2013608.","journal-title":"Expert Opin Drug Saf"},{"key":"15_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10156-005-0385-Z","volume":"11","author":"C Sarrecchia","year":"2005","unstructured":"Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother. 2005;11:189\u201391.","journal-title":"J Infect Chemother"},{"key":"15_CR36","first-page":"1507","volume":"24","author":"YH Li","year":"2005","unstructured":"Li YH, He YF, Wang FH, Lin XB, Xia ZJ, Sun XF, et al. Clinical analysis of liver damage of 116 malignant lymphoma patients with chronic HBV infection after cytotoxic chemotherapy. Chin J Cancer. 2005;24:1507\u20139.","journal-title":"Chin J Cancer"},{"key":"15_CR37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cncr.24742","volume":"116","author":"YX Koo","year":"2010","unstructured":"Koo YX, Tan DS, Tan IB, Tao M, Chow WC, Lim ST. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer. 2010;116:115\u201321.","journal-title":"Cancer"},{"key":"15_CR38","first-page":"988","volume":"34","author":"Chinese Society of Hematology, CMA, Committee of Malignant Lymphoma, Chinese Anti-cancer Association, Chinese Society of Hepatology, CMA","year":"2013","unstructured":"Chinese Society of Hematology, CMA, Committee of Malignant Lymphoma, Chinese Anti-cancer Association, Chinese Society of Hepatology, CMA. Consensus on the management of lymphoma with HBV infection. Zhonghua Xue Ye Xue Za Zhi. 2013;34:988\u201393 [in Chinese]","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"15_CR39","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","volume":"125","author":"AS Lok","year":"2003","unstructured":"Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714\u201322.","journal-title":"Gastroenterology"},{"key":"15_CR40","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","volume":"31","author":"YH Huang","year":"2013","unstructured":"Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31:2765\u201372.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"15_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/annonc\/8.suppl_1.S107","volume":"8","author":"K Kumagai","year":"1997","unstructured":"Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol. 1997;8 Suppl 1:107\u20139.","journal-title":"Ann Oncol"}],"container-title":["Chinese Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-015-0015-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40880-015-0015-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-015-0015-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-015-0015-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T06:46:24Z","timestamp":1717915584000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancercommun.biomedcentral.com\/articles\/10.1186\/s40880-015-0015-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,28]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["15"],"URL":"https:\/\/doi.org\/10.1186\/s40880-015-0015-9","relation":{},"ISSN":["1944-446X"],"issn-type":[{"value":"1944-446X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,28]]},"assertion":[{"value":"17 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"18"}}